DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 52 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2023$57,036,596
+1.1%
57,791,0000.0%1.27%
+8.9%
Q4 2022$56,418,464
+0.6%
57,791,0000.0%1.17%
+4.6%
Q3 2022$56,098,000
-0.1%
57,791,0000.0%1.12%
-3.5%
Q2 2022$56,158,000
+6.0%
57,791,0000.0%1.16%
-2.3%
Q1 2022$52,992,000
-2.6%
57,791,0000.0%1.18%
+3.9%
Q4 2021$54,417,000
+4.4%
57,791,0000.0%1.14%
+12.2%
Q3 2021$52,121,000
+0.4%
57,791,0000.0%1.02%
+10.3%
Q2 2021$51,920,000
+9.2%
57,791,0000.0%0.92%
-7.7%
Q1 2021$47,537,000
+3.9%
57,791,0000.0%1.00%
+10.5%
Q4 2020$45,738,000
-1.7%
57,791,0000.0%0.90%
-20.2%
Q3 2020$46,521,000
+7.2%
57,791,0000.0%1.13%
-10.4%
Q2 2020$43,410,000
-7.3%
57,791,0000.0%1.26%
-14.9%
Q1 2020$46,815,000
-19.6%
57,791,0000.0%1.49%
-20.1%
Q4 2019$58,256,000
+17.6%
57,791,0000.0%1.86%
-7.9%
Q3 2019$49,530,000
-3.6%
57,791,0000.0%2.02%
+9.4%
Q2 2019$51,380,000
-10.2%
57,791,0000.0%1.85%
-15.8%
Q1 2019$57,201,000
+7.9%
57,791,0000.0%2.19%
+3.3%
Q4 2018$53,020,000
+46.3%
57,791,000
+60.5%
2.12%
+63.5%
Q3 2018$36,248,000
+14.7%
36,000,0000.0%1.30%
+16.9%
Q2 2018$31,598,000
+10.5%
36,000,0000.0%1.11%
+12.0%
Q1 2018$28,596,000
-1.0%
36,000,0000.0%0.99%
-12.8%
Q4 2017$28,879,000
-27.2%
36,000,000
-29.4%
1.14%
-36.4%
Q3 2017$39,674,000
+80.5%
51,000,000
+126.7%
1.79%
+52.3%
Q2 2017$21,983,000
-44.4%
22,500,000
-47.1%
1.17%
-23.1%
Q1 2017$39,540,00042,500,0001.52%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2020
NameSharesValueWeighting ↓
SILVERBACK ASSET MANAGEMENT LLC 12,851,000$12,016,0002.95%
Context Capital Management, LLC 3,000,000$2,804,0002.24%
Man Investments (CH) AG 3,000,000$2,798,0001.76%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 42,500,000$39,540,0001.52%
MACKAY SHIELDS LLC 17,069,000$15,982,0000.73%
HIGHFIELDS CAPITAL MANAGEMENT LP 73,035,000$68,425,0000.63%
WOLVERINE ASSET MANAGEMENT LLC 42,307,000$39,554,0000.61%
LINDEN ADVISORS LP 14,122,000$13,194,0000.49%
GLG LLC 9,100,000$8,486,0000.47%
Jabre Capital Partners S.A. 3,400,000$3,179,0000.38%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders